Verition Fund Management’s KalVista Pharmaceuticals KALV Stock Holding History

Verition Fund Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,500	Closed	-$513K	–	2308
2026 Q1	$513K	Buy	+25,500	New	+$411K	﹤0.01%	1580
2024 Q3	–	Sell	-15,113	Closed	-$178K	–	3363
2024 Q2	$178K	Buy	+15,113	New	+$176K	﹤0.01%	2630
2020 Q1	–	Sell	-31,065	Closed	-$553K	–	837
2019 Q4	$553K	Buy	+31,065	New	+$405K	0.01%	635

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Verition Fund Management's KALV Position: Q2 2026 in Review

Verition Fund Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 25,500 shares — an estimated $513K sold.

Verition Fund Management first reported a position in KALV in Q4 2019 and held it in 3 quarters. The position peaked at $553K in Q4 2019. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Verition Fund Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Verition Fund Management sold 25,500 KalVista Pharmaceuticals shares in Q2 2026, an estimated $513K.
Verition Fund Management first reported a position in KalVista Pharmaceuticals in Q4 2019 and held it in 3 quarters.
Verition Fund Management's KalVista Pharmaceuticals position peaked at $553K in Q4 2019.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.